Rep. Kevin Hern Sells Becton, Dickinson and Company (NYSE:BDX) Stock

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Becton, Dickinson and Company (NYSE:BDX). In a filing disclosed on April 03rd, the Representative disclosed that they had sold between $15,001 and $50,000 in Becton, Dickinson and Company stock on March 17th. The trade occurred in the Representative’s “HERN FAMILY REVOCABLE TRUST” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Exact Sciences (NASDAQ:EXAS) on 3/24/2026.
• Sold $50,001 – $100,000 in shares of Prologis (NYSE:PLD) on 3/20/2026.
• Sold $15,001 – $50,000 in shares of T. Rowe Price Group (NASDAQ:TROW) on 3/20/2026.
• Sold $15,001 – $50,000 in shares of Medtronic (NYSE:MDT) on 3/20/2026.
• Sold $500,001 – $1,000,000 in shares of Texas Instruments (NASDAQ:TXN) on 3/18/2026.
• Sold $500,001 – $1,000,000 in shares of Smartstop Self Storage REIT (NYSE:SMA) on 3/18/2026.
• Sold $50,001 – $100,000 in shares of BlackRock MuniAssets Fund (NYSE:MUA) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Cognizant Technology Solutions (NASDAQ:CTSH) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Invesco (NYSE:IVZ) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Comcast (NASDAQ:CMCSA) on 3/17/2026.

Becton, Dickinson and Company Price Performance

NYSE BDX traded down $0.66 during trading hours on Tuesday, reaching $154.67. The company’s stock had a trading volume of 285,499 shares, compared to its average volume of 2,719,171. The firm’s 50-day moving average price is $174.72 and its 200-day moving average price is $186.24. The company has a quick ratio of 0.58, a current ratio of 1.05 and a debt-to-equity ratio of 0.67. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35. The company has a market capitalization of $44.04 billion, a price-to-earnings ratio of 25.23, a PEG ratio of 11.20 and a beta of 0.29.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.81 by $0.10. The business had revenue of $4.49 billion for the quarter, compared to analysts’ expectations of $5.15 billion. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The company’s revenue for the quarter was up 1.6% on a year-over-year basis. During the same period in the prior year, the firm earned $3.43 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, equities research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company declared that its board has approved a share buyback program on Tuesday, January 27th that allows the company to repurchase $10.00 million in outstanding shares. This repurchase authorization allows the medical instruments supplier to repurchase up to 0% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s management believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th were issued a $1.05 dividend. The ex-dividend date of this dividend was Tuesday, March 10th. This represents a $4.20 dividend on an annualized basis and a yield of 2.7%. Becton, Dickinson and Company’s payout ratio is currently 68.52%.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of BDX. Bank of New Hampshire increased its position in shares of Becton, Dickinson and Company by 40.2% during the fourth quarter. Bank of New Hampshire now owns 1,178 shares of the medical instruments supplier’s stock worth $229,000 after purchasing an additional 338 shares in the last quarter. World Investment Advisors lifted its stake in shares of Becton, Dickinson and Company by 24.7% in the 4th quarter. World Investment Advisors now owns 25,141 shares of the medical instruments supplier’s stock valued at $4,879,000 after purchasing an additional 4,984 shares during the last quarter. Winthrop Partners WNY LLC acquired a new position in shares of Becton, Dickinson and Company in the 4th quarter valued at $306,000. Larry Mathis Financial Planning LLC purchased a new stake in shares of Becton, Dickinson and Company in the 4th quarter valued at $281,000. Finally, Auto Owners Insurance Co raised its holdings in shares of Becton, Dickinson and Company by 22,225.2% in the 4th quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock valued at $790,079,000 after buying an additional 40,528,680 shares during the period. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on BDX shares. Citigroup decreased their price objective on Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating on the stock in a report on Tuesday, February 10th. Stifel Nicolaus increased their price target on Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Argus cut their price objective on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating on the stock in a research report on Monday, March 23rd. Zacks Research downgraded Becton, Dickinson and Company from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 11th. Finally, Bank of America increased their price target on Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a research report on Monday, January 5th. Six analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $191.62.

Insider Activity

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of the company’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the sale, the executive vice president owned 12,095 shares in the company, valued at $2,509,228.70. This represents a 11.75% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Bertram L. Scott sold 953 shares of the company’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total value of $174,027.33. Following the completion of the sale, the director directly owned 36,763 shares of the company’s stock, valued at approximately $6,713,291.43. This trade represents a 2.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 2,713 shares of company stock worth $536,881. 0.40% of the stock is owned by company insiders.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.